WellDoc® announces the appointments of Dr. David Levy, Terry Lierman, Donald Almeida and Michael Greenebaum to its Board of Directors. In addition, the company has formed a new strategic advisory board that includes Dr. Michael Stocker, Rt Hon Alan Milburn, H. Tom Watkins, and Christopher T. Rogers. These global healthcare and technology executives add experience and guidance to the company during the launch and commercialization of BlueStar™, the first FDA cleared, reimbursable, mobile prescription therapy for type 2 diabetes.
“I’m humbled to serve the company alongside individuals who literally crafted today’s ground breaking healthcare policies both in the U.S. and in Europe and who have built multi-billion dollar successful businesses” “We are proud to welcome David, Terry, Don and Michael to our Board of Directors and Mike, Alan, Tom, and Chris as advisors,” stated Ryan Sysko, Founder and CEO of WellDoc. “Each addition brings unique local and global experiences from private industry, healthcare, technology, and policymaking backgrounds. Their collective knowledge will be invaluable to the growth of our company.”